Literature DB >> 17222465

Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission.

David J Dooley1, Charles P Taylor, Sean Donevan, Douglas Feltner.   

Abstract

The term 'Ca2+ channel alpha2delta ligands' has recently been applied to an evolving drug class that includes gabapentin (Neurontin) and pregabalin (Lyrica), and reflects significant progress over the past decade in elucidating the mechanism of action of these drugs: a novel, specific action at one of the subunits constituting voltage-sensitive Ca2+ channels. Binding of these ligands to the alpha2delta subunit is considered to explain their usefulness in treating several clinical disorders, including epilepsy, pain from diabetic neuropathy, postherpetic neuralgia and fibromyalgia, and generalized anxiety disorder. The evidence indicates a relationship between alpha2delta subunit binding and the modulation of processes that subserve neurotransmission. This modulation is characterized by a reduction of the excessive neurotransmitter release that is observed in certain neurological and psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222465     DOI: 10.1016/j.tips.2006.12.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  97 in total

Review 1.  The discovery and development of analgesics: new mechanisms, new modalities.

Authors:  Gillian Burgess; Dic Williams
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

2.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  Patterned expression of ion channel genes in mouse dorsal raphe nucleus determined with the Allen Mouse Brain Atlas.

Authors:  J Scott Templin; Sun Jung Bang; Mariano Soiza-Reilly; Charles B Berde; Kathryn G Commons
Journal:  Brain Res       Date:  2012-04-04       Impact factor: 3.252

4.  alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?

Authors:  Michael Camilleri
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

5.  Pregabalin for painful diabetic peripheral neuropathy.

Authors:  Lee C Rogers; David G Armstrong
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-11-18

Review 6.  Pregabalin: a review of its use in fibromyalgia.

Authors:  Katherine A Lyseng-Williamson; M Asif A Siddiqui
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis.

Authors:  Cagla Eroglu; Nicola J Allen; Michael W Susman; Nancy A O'Rourke; Chan Young Park; Engin Ozkan; Chandrani Chakraborty; Sara B Mulinyawe; Douglas S Annis; Andrew D Huberman; Eric M Green; Jack Lawler; Ricardo Dolmetsch; K Christopher Garcia; Stephen J Smith; Z David Luo; Arnon Rosenthal; Deane F Mosher; Ben A Barres
Journal:  Cell       Date:  2009-10-08       Impact factor: 41.582

8.  Hypothalamic dysfunction of the thrombospondin receptor α2δ-1 underlies the overeating and obesity triggered by brain-derived neurotrophic factor deficiency.

Authors:  Joshua W Cordeira; Jennifer A Felsted; Sarah Teillon; Shabrine Daftary; Micaella Panessiti; Jena Wirth; Miguel Sena-Esteves; Maribel Rios
Journal:  J Neurosci       Date:  2014-01-08       Impact factor: 6.167

9.  Modeling sleep data for a new drug in development using markov mixed-effects models.

Authors:  Maria C Kjellsson; Daniele Ouellet; Brian Corrigan; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-06-17       Impact factor: 4.200

10.  Biallelic GRM7 variants cause epilepsy, microcephaly, and cerebral atrophy.

Authors:  Dana Marafi; Tadahiro Mitani; Sedat Isikay; Jozef Hertecant; Mohammed Almannai; Kandamurugu Manickam; Rami Abou Jamra; Ayman W El-Hattab; Jaishen Rajah; Jawid M Fatih; Haowei Du; Ender Karaca; Yavuz Bayram; Jaya Punetha; Jill A Rosenfeld; Shalini N Jhangiani; Eric Boerwinkle; Zeynep C Akdemir; Serkan Erdin; Jill V Hunter; Richard A Gibbs; Davut Pehlivan; Jennifer E Posey; James R Lupski
Journal:  Ann Clin Transl Neurol       Date:  2020-04-14       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.